Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Partial down-titration of guideline-directed medical therapy in heart failure in remission
2025-522560-32-01Phase 4Authorised
- Sponsor
- Ziekenhuis Oost-Limburg
- Start
- Mar 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone, bisoprolol, empagliflozin and lisinopril in heart failure (HF) (2 arms), sponsored by Ziekenhuis Oost-Limburg. Primary endpoints: Left ventricular remodeling, NT-proBNP increase and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
spironolactonebisoprololempagliflozinlisinopril
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2025-522560-32-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522560-32-01.